Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether hepatitis B immunoglobin can be discontinued early after hepatitis B virus (HBV) induced liver transplantation and be replaced by the nucleoside analogue entecavir to prevent hepatitis B reinfection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HepNet Study House, German Liverfoundation
• Collaborator: Hannover Medical School
• Treatments: Entecavir

Criteria

Inclusion Criteria:

• liver transplantation for hepatitis B induced endstage liver disease

• absence of coinfection with HIV and HCV

• female and male patients >= 18 years of age

Exclusion Criteria:

• any evidence of other causes for endstage liver disease

• patients that do not fulfill the criteria for liver transplantation